Glibenclamide-Loaded Nanoparticles Reduce NLRP3 Inflammasome Activation and Modulate miR-223-3p/miR-7-1-5p Expression in THP-1 Cells.
NLRP3 inflammasome
glibenclamide
microRNAs
nanoparticles
rehabilitation
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
10 Nov 2023
10 Nov 2023
Historique:
received:
19
10
2023
revised:
07
11
2023
accepted:
08
11
2023
medline:
25
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
The anti-hyperglycemic drug glibenclamide (Glb) might represent an interesting therapeutic option in human neurodegenerative diseases because of its anti-inflammatory activity and its ability to downregulate activation of the NLRP3 inflammasome. Bi-functionalized liposomes that can cross the blood-brain barrier (BBB) may be used to release Glb into the central nervous system (CNS), overcoming its poor solubility and bioavailability. Here, we analyzed in vitro the effect of Glb-loaded nanovectors (GNVs) and Glb itself on NLRP3 inflammasome activation using a lipopolysaccharide- and nigericine-activated THP-1 cell model. Apoptosis-associated speck-like protein containing a CARD (ASC) aggregation and NLRP3-related cytokine (IL-1β, caspase 1, and IL-18) production and gene expression, as well as the concentration of miR-223-3p and miR-7-1-5p, known to modulate the NLRP3 inflammasome, were evaluated in all conditions. Results showed that both GNVs and Glb reduced significantly ASC-speck oligomerization, transcription and translation of NLRP3, as well as the secretion of caspase 1 and IL-1β (
Identifiants
pubmed: 38004455
pii: ph16111590
doi: 10.3390/ph16111590
pmc: PMC10675475
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Regione Lombardia
ID : FRRB CP2_16/2018
Organisme : Ministero della Salute
ID : Ricerca Corrente 2022-2023
Organisme : Ministero della Salute
ID : PNRR Project MNESYS code: PE00000006-B43D22000650006
Organisme : Fondazione Alessandro e Vincenzo Negroni Prati Morosini
ID : 2023
Organisme : Fondazione Romeo ed Enrica Invernizzi
ID : 2023
Références
Gene Expr Patterns. 2009 Apr;9(4):193-9
pubmed: 19135553
Front Immunol. 2018 May 04;9:983
pubmed: 29780394
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Immunol Cell Biol. 2017 Aug;95(7):584-592
pubmed: 28356568
Neurology. 2018 Dec 4;91(23):e2163-e2169
pubmed: 30446594
J Leukoc Biol. 2018 Sep;104(3):515-524
pubmed: 29969525
J Cereb Blood Flow Metab. 2009 Feb;29(2):317-30
pubmed: 18854840
AAPS J. 2021 Oct 28;23(6):114
pubmed: 34713363
Cell Death Differ. 2007 Sep;14(9):1583-9
pubmed: 17599094
Mol Cell Biol. 1995 Jan;15(1):58-68
pubmed: 7799967
Mol Neurodegener. 2016 Apr 16;11:28
pubmed: 27084336
Cell Biosci. 2020 Jun 10;10:77
pubmed: 32537124
Eur J Pharmacol. 2017 Sep 15;811:74-86
pubmed: 28576406
Front Aging Neurosci. 2021 Oct 29;13:754123
pubmed: 34776934
Mediators Inflamm. 2022 Feb 11;2022:8457010
pubmed: 35185385
Front Neurol. 2022 Mar 11;13:819911
pubmed: 35359635
Mediators Inflamm. 2017;2017:3578702
pubmed: 28740332
Pharmaceutics. 2022 Nov 07;14(11):
pubmed: 36365220
Cell Metab. 2007 Aug;6(2):137-43
pubmed: 17681149
Stroke. 2018 Jun;49(6):1457-1463
pubmed: 29789393
Pharmaceuticals (Basel). 2021 Nov 20;14(11):
pubmed: 34832969
Mol Neurodegener. 2016 Mar 03;11:23
pubmed: 26939933
Sci Rep. 2016 Feb 12;6:21044
pubmed: 26869018
Immunology. 2021 Jan;162(1):44-57
pubmed: 32852789
PLoS One. 2015 Jul 30;10(7):e0134476
pubmed: 26225433
J Immunol. 2012 Oct 15;189(8):4175-81
pubmed: 22984082
Cells. 2022 Jul 12;11(14):
pubmed: 35883623
Int Immunopharmacol. 2014 Nov;23(1):37-45
pubmed: 25130606
J Clin Invest. 2015 Nov 2;125(11):4149-59
pubmed: 26436647
J Cell Biol. 2009 Oct 5;187(1):61-70
pubmed: 19805629
J Biol Chem. 2019 May 24;294(21):8325-8335
pubmed: 30940725
J Alzheimers Dis. 2019;72(2):401-412
pubmed: 31594217
Pharmaceutics. 2022 Apr 11;14(4):
pubmed: 35456671
J Dent Res. 2020 Jul;99(7):830-838
pubmed: 32202959
Arthritis Res Ther. 2018 Feb 26;20(1):34
pubmed: 29482609
Prog Biophys Mol Biol. 2020 Jan;150:50-61
pubmed: 31100298
FEBS Lett. 2001 Jun 15;499(1-2):154-60
pubmed: 11418131
Front Aging Neurosci. 2022 Jun 10;14:879021
pubmed: 35754962
Biochem Biophys Res Commun. 2008 Feb 22;366(4):922-6
pubmed: 18086561
Nature. 2007 Jun 28;447(7148):1116-20
pubmed: 17515919
PLoS One. 2013 Aug 01;8(8):e70622
pubmed: 23936458
Front Neurosci. 2021 Mar 25;15:639646
pubmed: 33867921
Int J Mol Sci. 2019 Jul 06;20(13):
pubmed: 31284572
PLoS One. 2012;7(8):e42971
pubmed: 22937006